The positive and high-positive rates of RAD21 in the malignant tumor group (93.69% and 70.53%, respectively) were significantly higher than those in the borderline tumor group (60.00% and 33.33%, respectively), benign tumor group (36.36% and 9.09%, respectively), and normal ovary group (22.22% and 0.00%, respectively). This evidence concerns the gene RAD21 and benign neoplasm.